Skip to content
Invokana(canagliflozin)
Invokamet, Invokana, Vokanamet (canagliflozin) is a small molecule pharmaceutical. Canagliflozin was first approved as Invokana on 2013-03-29. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against sodium/glucose cotransporter 2. In addition, it is known to target sodium/glucose cotransporter 1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
Trade Name
FDA
EMA
Invokana
Combinations
Invokamet
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Canagliflozin
Tradename
Company
Number
Date
Products
INVOKANAJohnson & JohnsonN-204042 RX2013-03-29
2 products, RLD, RS
Canagliflozin
+
Metformin hydrochloride
Tradename
Company
Number
Date
Products
INVOKAMETJohnson & JohnsonN-204353 RX2014-08-08
4 products, RLD, RS
INVOKAMET XRJohnson & JohnsonN-205879 RX2016-09-20
4 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
invokamet invokamet xrNew Drug Application2022-10-20
invokanaNew Drug Application2022-12-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
type 2 diabetes mellitusEFO_0001360D003924E11
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Canagliflozin, Invokana, Janssen Pharms
106176682031-05-11DPU-493, U-2441, U-2632, U-2794, U-2795, U-2796, U-2797, U-2798, U-2799
79435822029-02-26DS, DPU-493, U-2441, U-2632
85132022027-12-03DS, DPU-493, U-2441, U-2632
79437882027-07-14DS, DP
82222192025-04-11U-493, U-2441, U-2632
Canagliflozin / Metformin Hydrochloride, Invokamet, Janssen Pharms
115768942030-07-06DP
87854032024-07-30DP
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BD: Combinations of oral blood glucose lowering drugs
— A10BD16: Metformin and canagliflozin
— A10BK: Sodium-glucose co-transporter 2 (sglt2) inhibitors
— A10BK02: Canagliflozin
HCPCS
No data
Clinical
Clinical Trials
128 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E111162019862
ObesityD009765EFO_0001073E66.9—2—3—5
Cardiovascular diseasesD002318EFO_0000319I98——1214
Diabetes mellitusD003920EFO_0000400E08-E13——12—3
OverweightD050177E66.3———112
Systolic heart failureD054143EFO_1001207I50.20———1—1
HyperuricemiaD033461———1—1
GoutD006073EFO_0004274M10———1—1
AlbuminuriaD000419EFO_0004285R80.9———1—1
HypertensionD006973EFO_0000537I10———1—1
Show 1 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart failureD006333EFO_0003144I50——2—13
Diabetic nephropathiesD003928EFO_0000401—12——3
Renal insufficiencyD051437HP_0000083N191—1——2
Risk factorsD012307EFO_0003919——1——1
Coronary artery diseaseD003324I25.1—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 1 diabetes mellitusD003922EFO_0001359E10—1——12
Breast neoplasmsD001943EFO_0003869C5012———2
Colorectal neoplasmsD01517911———1
Endometrial neoplasmsD016889EFO_000423011———1
Head and neck neoplasmsD00625811———1
Lung neoplasmsD008175C34.9011———1
Polycystic ovary syndromeD011085EFO_0000660E28.211———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—44————44
Therapeutic equivalencyD0138101————1
Plasma volumeD0109531————1
Hepatic insufficiencyD0485501————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypoglycemiaD007003HP_0001943E16.2————11
Prediabetic stateD011236EFO_1001121R73.03————11
HivD006678O98.7————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCANAGLIFLOZIN
INNcanagliflozin
Description
Canagliflozin is a C-glycosyl compound that is used (in its hemihydrate form) for treatment of type II diabetes via inhibition of sodium-glucose transport protein subtype 2. It has a role as a hypoglycemic agent and a sodium-glucose transport protein subtype 2 inhibitor. It is a C-glycosyl compound, a member of thiophenes and an organofluorine compound.
Classification
Small molecule
Drug classphlorozin derivatives, phenolic glycosides
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O
Identifiers
PDB—
CAS-ID842133-18-0
RxCUI1546031
ChEMBL IDCHEMBL4594217
ChEBI ID—
PubChem CID24812758
DrugBankDB08907
UNII ID6S49DGR869 (ChemIDplus, GSRS)
Target
Agency Approved
SLC5A2
SLC5A2
Organism
Homo sapiens
Gene name
SLC5A2
Gene synonyms
SGLT2
NCBI Gene ID
6524
Protein name
sodium/glucose cotransporter 2
Protein synonyms
Low affinity sodium-glucose cotransporter, Na(+)/glucose cotransporter 2, solute carrier family 5 (sodium/glucose cotransporter), member 2, solute carrier family 5 (sodium/glucose transporter), member 2, Solute carrier family 5 member 2
Uniprot ID
P31639
Mouse ortholog
Slc5a2 (246787)
sodium/glucose cotransporter 2 (Q923I7)
Alternate
SLC5A1
SLC5A1
Organism
Homo sapiens
Gene name
SLC5A1
Gene synonyms
NAGT, SGLT1
NCBI Gene ID
6523
Protein name
sodium/glucose cotransporter 1
Protein synonyms
High affinity sodium-glucose cotransporter, Na+/glucose cotransporter 1, solute carrier family 5 (sodium/glucose cotransporter), member 1, Solute carrier family 5 member 1
Uniprot ID
P13866
Mouse ortholog
Slc5a1 (20537)
sodium/glucose cotransporter 1 (Q8C3K6)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 6,641 documents
View more details
Safety
Black-box Warning
Black-box warning for: Invokamet invokamet xr
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
15,291 adverse events reported
View more details